{"nctId":"NCT01543178","briefTitle":"Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study","startDateStruct":{"date":"2012-02"},"conditions":["Irritable Bowel Syndrome With Diarrhea"],"count":2583,"armGroups":[{"label":"Rifaximin open-label","type":"EXPERIMENTAL","interventionNames":["Drug: open-label rifaximin"]},{"label":"Double-blind rifaximin (retreatment)","type":"EXPERIMENTAL","interventionNames":["Drug: open-label rifaximin","Drug: double-blind rifaximin"]},{"label":"Double-blind placebo (retreatment)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: open-label rifaximin","Drug: double-blind placebo"]}],"interventions":[{"name":"open-label rifaximin","otherNames":["rifaximin"]},{"name":"double-blind placebo","otherNames":["Placebo"]},{"name":"double-blind rifaximin","otherNames":["rifaximin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* IBS confirmed by Rome III diagnostic criteria.\n* At least 18 years of age.\n* Colonoscopy within the past 10 years to rule out inflammatory bowel disease; or flexible sigmoidoscopy if \\< 50 years of age or previous colonoscopy \\> 10 years prior.\n* Willing to maintain a stable diet. including vitamins, supplements, and nutraceuticals.\n\nExclusion Criteria:\n\n* Diabetes (Type 1 or 2).\n* Lactose intolerance and not controlled by a lactose-free diet.\n* Pregnant or planning to become pregnant or is lactating.\n* History of HIV or hepatitis B or C.\n* Participation in investigational study within past 30 days.\n* Taking rifaximin or any other antibiotic within past 60 days.\n* Unstable cardiovascular or pulmonary disease, with change in treatment in last 30 days due to worsening disease condition.\n* History of GI surgery.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Repeat Treatment Responders","description":"Subjects who respond to repeat treatment in both IBS-related abdominal pain and stool consistency. The proportion of patients who responded to repeat treatment during the first double-blind repeat treatment phase is presented. Response is defined as improvement from baseline in abdominal pain AND reduction from baseline in diarrhea.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":2579},"commonTop":["Nausea","Upper respiratory tract infection","Urinary tract infection","Nasopharyngitis","Headache"]}}}